Proper detection and accurate characterization of Non-Small Cell Lung Cancer (NSCLC) are an open challenge in the imaging field. Biomedical imaging is fundamental in lung cancer assessment and offers the possibility of calculating predictive biomarkers impacting patients' management. Within this context, radiomics, which consists of extracting quantitative features from digital images, shows encouraging results for clinical applications, but the sub-optimal standardization of the procedure and the lack of definitive results are still a concern in the field. For these reasons, this work proposes the design and development of LuCIFEx, a fully-automated pipeline for non-invasive in-vivo characterization of NSCLC, aiming to speed up the analysis process and enable an early diagnosis of the tumor.LuCIFEx pipeline relies on routinely acquired [18F]FDG-PET/CT images for the automatic segmentation of the cancer lesion, allowing the computation of accurate radiomic features, then employed for cancer characterization through Machine Learning algorithms. The proposed multi-stage segmentation process can identify the lesion with a mean accuracy of 94.2±5.0%. Finally, the proposed data analysis pipeline demonstrates the potential of PET/CT features for the automatic recognition of lung metastases and NSCLC histological subtypes, while highlighting the main current limitations of the radiomic approach.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1109/JBHI.2022.3156984 | DOI Listing |
BMJ Oncol
July 2024
Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Objective: To evaluate signal transducer and activator of transcription 3 (STAT3) inhibition we conducted a co-clinical trial testing danvatirsen, a STAT3 antisense oligonucleotide (ASO) and checkpoint inhibition in conjunction with preclinical experiments.
Methods And Analysis: Orthotopically implanted pancreatic cancer (pancreatic adenocarcinoma (PDAC)) was treated with STAT3 ASO with immune checkpoint inhibition. Tumour infiltrating immune cell populations were characterised via flow cytometry.
J Thorac Oncol
January 2025
Medical University of South Carolina, Division of Pulmonary and Critical Care Medicine. Charleston, SC. Electronic address:
Unlabelled: IntroductionAs the U.S. population ages more octogenarians are undergoing surgical resection for lung cancer (LC).
View Article and Find Full Text PDFJ Med Chem
January 2025
Chief executive officer, Jacobio Pharmaceuticals Group Co., Ltd., Beijing100176, P. R. China.
KRAS is the most frequently mutated driver oncogene in human cancer, and KRAS mutation is commonly found in non-small-cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC). Inhibitors that covalently modify the mutated codon 12 cysteine have completed proof-of-concept studies in the clinic. Here, we describe structure-based design and cocrystal-aided drug optimization of a series of compounds with the 1,8-naphthyridine-3-carbonitrile scaffold.
View Article and Find Full Text PDFCancer Med
February 2025
Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Introduction: Immune checkpoint inhibitors (ICI) have improved the therapeutic arsenal in outpatient oncology care; however, data on necessity of hospitalizations associated with immune-related adverse events (irAEs) are scarce. Here, we characterized hospitalizations of patients undergoing ICI, from the prospective cohort study of the immune cooperative oncology group (ICOG) Hannover.
Methods: Between 12/2019 and 06/2022, 237 patients were included.
J Thorac Oncol
January 2025
Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address:
Background: Mutations in STK11, KEAP1, and SMARCA4 predispose to inferior immune checkpoint inhibitor (ICI) efficacy in non-small cell lung cancer (NSCLC), particularly among KRAS-mutant cases. However, the frequency, clinicopathologic features, and clinical impact of deletions in these genes are poorly characterized.
Methods: Clinicopathologic correlates of STK11, KEAP1, and SMARCA4 deletion were analyzed in nonsquamous NSCLCs at Dana-Farber Cancer Institute (DFCI).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!